FGL (NCAM-Derived Peptide)
FGL (FG Loop peptide) is a synthetic peptide derived from the second fibronectin type III domain of neural cell adhesion molecule (NCAM). It activates FGFR1 to promote neuroprotection, synaptic plasticity, and cognitive function, with preclinical efficacy in Alzheimer's disease and neuroinflammation models.
Overview
Neural cell adhesion molecule (NCAM) is a member of the immunoglobulin superfamily that mediates cell-cell adhesion and signaling critical for nervous system development and plasticity. Beyond homophilic NCAM-NCAM binding, NCAM engages heterophilic partners including FGFR1, FGFR2, GDNF family ligand receptors, and the prion protein. The interaction between NCAM's FnIII-2 domain and FGFR1 activates neurotrophic signaling that supports long-term potentiation (LTP), memory consolidation, and neuronal survival (Bhatt et al., 2023).
FGL was rationally designed by Kiselyov, Bhatt, and colleagues at the University of Copenhagen by identifying the minimal NCAM sequence required for FGFR1 activation. The peptide is typically synthesized as a tetramer (four copies linked to a lysine backbone) to increase avidity and receptor clustering -- critical for effective FGFR1 activation (Kiselyov et al., 2003). This dendrimeric design mimics the multivalent presentation of NCAM on the cell surface and enhances biological potency over the monomeric peptide.
Mechanism of Action
FGL activates FGFR1 by binding to the receptor's extracellular domain at a site overlapping but distinct from canonical FGF ligand binding. This triggers receptor dimerization and autophosphorylation, but with distinct kinetics compared to FGF-induced activation -- FGL produces sustained, moderate FGFR1 activation rather than the transient, high-amplitude response elicited by FGF2 (Bhatt et al., 2023).
FGFR1 activation and downstream cascades:
- MAPK/ERK pathway: FGL-induced FGFR1 phosphorylation activates Ras-Raf-MEK-ERK1/2, promoting neuronal differentiation and survival. ERK activation peaks at 15-30 minutes and sustains for 2-4 hours (Neiiendam et al., 2004)
- PI3K/Akt pathway: Parallel activation of PI3K leads to Akt phosphorylation at Ser473, inhibiting pro-apoptotic factors (Bad, caspase-9, GSK-3beta) and promoting cell survival
- PLCgamma/CaMKII pathway: FGFR1-dependent PLCgamma activation elevates intracellular calcium and activates CaMKII, which is critical for LTP induction and memory consolidation (Bhatt et al., 2023)
- CREB phosphorylation: Convergent ERK and CaMKII signaling activates CREB at Ser133, driving expression of plasticity-related genes including BDNF, Arc, and c-Fos
Anti-inflammatory mechanism: FGL suppresses microglial activation by inhibiting NF-kappaB nuclear translocation and reducing pro-inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6) while increasing anti-inflammatory IL-10 in activated microglia (Downer et al., 2010).
Reconstitution Calculator
Research
Synaptic Plasticity and Memory
FGL enhances hippocampal long-term potentiation (LTP) and improves memory in multiple behavioral paradigms. In rat hippocampal slices, FGL facilitates LTP induction at Schaffer collateral-CA1 synapses via FGFR1-dependent mechanisms (Bhatt et al., 2023). In vivo, subcutaneous FGL administration (10 mg/kg) enhances spatial memory in the Morris water maze and object recognition tasks in aged rats (Bhatt et al., 2023). The memory-enhancing effects are blocked by the FGFR inhibitor SU5402 and by MEK inhibitor PD98059, confirming dependence on FGFR1-ERK signaling.
Importantly, FGL's effects on plasticity are distinct from FGF2: while FGF2 can be excitotoxic at high concentrations, FGL's moderate FGFR1 activation profile avoids this liability, making it a safer candidate for chronic neurotrophic therapy.
Cognitive Aging
Age-related cognitive decline is associated with reduced NCAM expression and decreased FGFR1 signaling in the hippocampus. FGL treatment in aged rats (22-24 months) restores hippocampal LTP to levels comparable to young adults and improves performance in spatial navigation tasks. The peptide upregulates synaptic markers including synaptophysin and PSD-95 in the hippocampal CA1 region, suggesting structural synaptic recovery (Bhatt et al., 2023).
Neuroinflammation
FGL modulates microglial phenotype from the neurotoxic M1 state toward the neuroprotective M2 state. In lipopolysaccharide (LPS)-challenged rats, systemic FGL administration reduces hippocampal TNF-alpha and IL-1beta levels while preserving IL-10 production (Downer et al., 2010). In mixed glial cultures, FGL suppresses LPS-induced iNOS expression and nitric oxide production. The mechanism involves FGL-mediated activation of FGFR1 on microglia, which inhibits IKK-dependent NF-kappaB activation.
Peripheral Nerve Regeneration
NCAM plays established roles in peripheral nerve regeneration, and FGL retains some of this activity. In sciatic nerve crush models, FGL promotes functional recovery and increases myelinated fiber density distal to the injury site. The peptide enhances Schwann cell proliferation and migration through FGFR1/ERK-dependent mechanisms (Bhatt et al., 2023).
Alzheimer's Disease Models
FGL has shown efficacy in multiple preclinical Alzheimer's disease models:
- APP/PS1 transgenic mice: Subcutaneous FGL administration (5.3 mg/kg, twice weekly for 3-4 weeks) reversed spatial memory deficits in the radial arm water maze and reduced hippocampal amyloid plaque-associated inflammation without affecting plaque load itself (Bhatt et al., 2023)
- Amyloid-beta oligomer models: FGL protects hippocampal neurons from Abeta(1-42) oligomer toxicity in vitro through FGFR1-dependent Akt activation. It also reverses Abeta-induced LTP impairment in hippocampal slices
- Neuroinflammation component: FGL reduces microglial activation surrounding amyloid plaques, decreasing the inflammatory milieu that accelerates neurodegeneration. This anti-inflammatory effect is independent of its direct neurotrophic activity (Downer et al., 2010)
The dual action of FGL -- direct neuroprotection via FGFR1 plus anti-inflammatory modulation of microglia -- positions it as a multi-target therapeutic candidate for AD, addressing both neuronal vulnerability and neuroinflammation.
NCAM-FGFR1 mimetic signaling
FGL is a 15-amino-acid peptide from the FG loop of NCAM that binds and activates FGFR1, triggering Ras-MAPK and PI3K-Akt pathways, CaMKII activity, and AMPA receptor trafficking to enhance plasticity and neuronal survival.
- FGL improves memory retention after fear-conditioning and water-maze training
- Reverses working-memory deficits in a phencyclidine model relevant to schizophrenia
Regeneration and anti-inflammation
Across stroke, aging, and epilepsy models FGL mobilizes endogenous neural stem cells, protects oligodendrocytes, and dampens microglial activation, supporting its profile as a neurotrophic and anti-inflammatory candidate.
- Enhances post-stroke neurogenesis and regenerative capacity
- Anti-inflammatory action restores cognition in aged rodents
Safety Profile
FGL has demonstrated a favorable preclinical safety profile across multiple rodent studies. At doses of 5-10 mg/kg administered subcutaneously 2-3 times weekly for up to 6 weeks, no significant adverse effects, organ toxicity, or behavioral abnormalities have been reported. The peptide does not appear to be immunogenic in rodent models, though the dendrimeric lysine backbone structure could theoretically elicit immune responses with chronic exposure in humans.
A key safety advantage of FGL over full FGF ligands is its inability to recruit heparan sulfate proteoglycans, which limits FGFR1 activation amplitude. This reduces the risk of mitogenic and potentially oncogenic signaling associated with sustained, high-level FGFR activation. FGL does not stimulate fibroblast or endothelial cell proliferation at neuroprotective concentrations, suggesting selectivity for neuronal and glial cell populations.
Theoretical concerns include:
- FGFR1-related oncogenicity: FGFR1 amplification is observed in some cancers (breast, lung, bladder). However, FGL's moderate, partial agonist activity at FGFR1 is mechanistically distinct from the constitutive FGFR1 activation seen in oncogenic contexts.
- Immune response: The tetrameric dendrimer structure could be immunogenic with repeated administration. No anti-FGL antibodies have been reported in preclinical studies, but this has not been systematically assessed.
- Off-target FGFR effects: While FGL shows selectivity for FGFR1, residual FGFR2/3 activation cannot be excluded at supratherapeutic doses.
No human safety data exist. Formal toxicology studies required for IND filing have not been publicly reported.
Pharmacokinetic Profile
FGL (NCAM-Derived Peptide) — Pharmacokinetic Curve
Subcutaneous, intraperitoneal (preclinical)Quick Start
- Route
- Subcutaneous, intraperitoneal (preclinical)
Research Indications
Primary Research Areas
FGL mimics NCAM-FGFR1 interaction to facilitate long-term memory and synaptic plasticity in learning paradigms.
FGL promotes neurite outgrowth, neural stem cell mobilization, and neuronal survival after ischemic and traumatic injury.
FGL acts as an anti-inflammatory agent restoring cognition and reducing neuropathology in aged and disease models.
FGL modulates network excitability and inflammation in kindling models.
Research Protocols
oral
- Optimized NCAM mimetics: Second-generation peptides based on the FGL scaffold with improved FGFR1 selectivity, enhanced BBB penetration, and oral bioavailability are under investigation (Bhatt et al., 2023).
intraperitoneal Injection
Clinical Research Protocols - Preclinical standard dose: 5-10 mg/kg subcutaneous or intraperitoneal, administered 2-3 times weekly in rodent models.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Preclinical standard dose | 5-10 mg | Once weekly | —(Route: Subcutaneous Injection, Intraperitoneal) |
subcutaneous Injection
In vivo, subcutaneous FGL administration (10 mg/kg) enhances spatial memory in the Morris water maze and object recognition tasks in aged rats (Bhatt et al., 2023). Clinical Research Protocols - Preclinical standard dose: 5-10 mg/kg subcutaneous or intraperitoneal, administered 2-3 times weekly in
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| General Research Protocol | 5-10 mg | Once weekly | 6 weeks(Route: Subcutaneous Injection) |
| Preclinical standard dose | 5-10 mg | Once weekly | —(Route: Subcutaneous Injection, Intraperitoneal) |
Interactions
Peptide Interactions
- Combination neurotrophin approaches: Preclinical studies exploring FGL in combination with BDNF mimetics (e.
What to Expect
What to Expect
Levels begin building after first administration; half-life of Not formally characterized.
Signaling kinetics: FGF2-FGFR1 signaling produces rapid, high-amplitude ERK phosphorylation (peak at 5-10 min, returning to baseline by 30 min)...
Duration: Typical preclinical protocols range from 2 weeks (acute neuroprotection) to 4-6 weeks (chronic cognitive studies).
At doses of 5-10 mg/kg administered subcutaneously 2-3 times weekly for up to 6 weeks, no significant adverse effects, organ toxicity, or behavioral...
FGL treatment in aged rats (22-24 months) restores hippocampal LTP to levels comparable to young adults and improves performance in spatial...
Quality Indicators
What to look for
- Human clinical trials conducted
- Extensive peer-reviewed research base
Caution
- Limited human data available
Frequently Asked Questions
References (17)
- [4]Downer EJ et al A synthetic NCAM-derived mimetic peptide, FGL, exerts anti-inflammatory properties via IGF-1 and interferon-gamma modulation J Neurochem (2010)
- [15]Leander et al — NCAM1 and its interacting partners in brain development and neuropsychiatric diseases Neurosci Biobehav Rev (2022)
- [1]Kiselyov VV et al Structural basis for a direct interaction between FGFR1 and NCAM and evidence for a regulatory role of ATP Structure (2003)
- [2]Neiiendam JL et al An NCAM-derived FGF-receptor agonist, the FGL peptide, induces neurite outgrowth and neuronal survival in primary rat neurons J Neurochem (2004)
- [3]
- [5]
- [7]Klementiev B et al A neural cell adhesion molecule-derived peptide reduces neuropathological signs and cognitive impairment induced by Abeta25-35 Neuroscience (2007)
- [8]Skibo GG et al A synthetic NCAM-derived peptide, FGL, protects hippocampal neurons from ischemic insult both in vitro and in vivo Eur J Neurosci (2005)
- [9]Dallerac G et al The neural cell adhesion molecule-derived peptide FGL facilitates long-term plasticity in the dentate gyrus in vivo Learn Mem (2011)
- [10]Ojo B et al A neural cell adhesion molecule-derived peptide, FGL, attenuates glial cell activation in the aged hippocampus Exp Neurol (2012)
- [11]Shi et al Neural cell adhesion molecule modulates mesenchymal stromal cell migration via MAPK/ERK signaling Exp Cell Res (2022)
- [14]
- [6]Secher T et al Analgesic effects of the NCAM-derived peptide FGL in the formalin test Brain Res (2006)
- [12]Hartz et al NCAM polysialylation in brain diseases Front Neurosci (2022)
- [13]Leander et al NCAM1 in brain development and neuropsychiatric diseases Neurosci Biobehav Rev (2022)
- [16]A cell adhesion molecule mimetic, FGL peptide, induces alterations in synapse and dendritic spine structure in the dentate gyrus of aged rats (2008)
→ FGL restructures synapses and dendritic spines in aged hippocampus, providing an ultrastructural basis for its memory-enhancing effects.
- [17]The NCAM-Derived Peptide FG Loop (FGL) Mobilizes Endogenous Neural Stem Cells and Promotes Regenerative Capacity after Stroke (2016)
→ Subcutaneous FGL enhanced neural stem cell mobilization and regeneration after middle cerebral artery occlusion.
Ferulic Acid
Ferulic acid is a phenolic compound found abundantly in plant cell walls, particularly in cereals, grains, fruits, and vegetables. It functions primarily as a p
Fisetin
Fisetin is a naturally occurring flavonoid found in fruits and vegetables (strawberries, apples, grapes) with senolytic properties, meaning it selectively elimi